April 24, 2019 10:54 AM EDTUpdated 11:08 AM
News Briefing

GSK plans $100M makeover of US man­u­fac­tur­ing site; La Jol­la Phar­ma gets a 'break­through' with late-stage drug

Kathy Wong

Editor

→ GSK $GSK an­nounced to­day that it will be in­vest­ing $100 mil­lion in­to its fa­cil­i­ty in Hamil­ton, MT to ex­pand long-term vac­cine man­u­fac­tur­ing ca­pa­bil­i­ties …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

Ky­owa Kirin ac­quires ex-US rights to Ku­ra’s leukemia treat­ment for $330M up­front

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times